AR087713A1 - Capacidad de respuesta a inhibidores de angiogenesis - Google Patents
Capacidad de respuesta a inhibidores de angiogenesisInfo
- Publication number
- AR087713A1 AR087713A1 ARP120103188A ARP120103188A AR087713A1 AR 087713 A1 AR087713 A1 AR 087713A1 AR P120103188 A ARP120103188 A AR P120103188A AR P120103188 A ARP120103188 A AR P120103188A AR 087713 A1 AR087713 A1 AR 087713A1
- Authority
- AR
- Argentina
- Prior art keywords
- bevacizumab
- patient
- genotype
- angiogenesis inhibitor
- conveniently treated
- Prior art date
Links
- 229940121369 angiogenesis inhibitor Drugs 0.000 title abstract 5
- 239000004037 angiogenesis inhibitor Substances 0.000 title abstract 5
- 229960000397 bevacizumab Drugs 0.000 abstract 6
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 abstract 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 108700028369 Alleles Proteins 0.000 abstract 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 abstract 2
- -1 bevacizumab Chemical compound 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se refiere a una composición farmacéutica que comprende un inhibidor de la angiogénesis, tal como bevacizumab, para el tratamiento de un paciente que sufre de un cáncer, basado en el genotipo del gen del promotor de VEGF y/o del gen VEGFR2. Se refiere además a un método para mejorar el efecto del tratamiento de quimioterapia de un paciente que sufre de cáncer, mediante la adición de un inhibidor de la angiogénesis, tal como bevacizumab, basado en el genotipo del gen del promotor de VEGF y/o del gen VEGFR2. Reivindicación 1: Método para determinar si un paciente resultará convenientemente tratado con una terapia que comprende un inhibidor de la angiogénesis que comprende bevacizumab o un anticuerpo que se une esencialmente al mismo epítopo de VEGF que el bevacizumab, comprendiendo dicho método: (a) determinar en una muestra derivada de un paciente que sufre de cáncer el genotipo en el polimorfismo rs699946 (SEC ID nº 1), e (b) identificar si un paciente resultará más o menos convenientemente tratado con una terapia con un inhibidor de angiogénesis que comprende bevacizumab o un anticuerpo que se une esencialmente al mismo epítopo de VEGF que el bevacizumab basándose en dicho genotipo, en el que la presencia de cada alelo A en el polimorfismo rs699946 (SEC ID nº 1) indica una probabilidad incrementada de que dicho paciente resulte más convenientemente tratado, o la presencia de cada alelo G en el polimorfismo rs699946 (SEC ID nº 1) indica una probabilidad incrementada de que dicho paciente resulte menos convenientemente tratado.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11179498 | 2011-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087713A1 true AR087713A1 (es) | 2014-04-09 |
Family
ID=46727238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103188A AR087713A1 (es) | 2011-08-31 | 2012-08-29 | Capacidad de respuesta a inhibidores de angiogenesis |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140294768A1 (es) |
| EP (1) | EP2751281A1 (es) |
| JP (1) | JP2014526900A (es) |
| KR (1) | KR20140064923A (es) |
| CN (1) | CN104024431A (es) |
| AR (1) | AR087713A1 (es) |
| AU (1) | AU2012300985A1 (es) |
| CA (1) | CA2845381A1 (es) |
| IL (1) | IL231164A0 (es) |
| MX (1) | MX2014002311A (es) |
| RU (1) | RU2014110271A (es) |
| SG (1) | SG10201607224PA (es) |
| WO (1) | WO2013030167A1 (es) |
| ZA (1) | ZA201400951B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200095641A1 (en) * | 2016-04-21 | 2020-03-26 | Vib Vzw | Means and methods for anti-vegf therapy |
| GR1009959B (el) * | 2019-06-21 | 2021-03-18 | ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε." | Οι πολυμορφισμοι σαν προβλεπτικοι παραγοντες στην ανταποκριση στη θεραπεια και τη συνολικη επιβιωση |
| KR102311480B1 (ko) | 2019-10-17 | 2021-10-12 | 한양대학교 산학협력단 | 일체형 스페이서, 이를 구비하는 수처리장치 및 스페이서의 제조 방법 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| NO870613L (no) | 1986-03-05 | 1987-09-07 | Molecular Diagnostics Inc | Deteksjon av mikroorganismer i en prve inneholdende nukleinsyre. |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| US5604099A (en) | 1986-03-13 | 1997-02-18 | Hoffmann-La Roche Inc. | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| US5310893A (en) | 1986-03-31 | 1994-05-10 | Hoffmann-La Roche Inc. | Method for HLA DP typing |
| US4851331A (en) | 1986-05-16 | 1989-07-25 | Allied Corporation | Method and kit for polynucleotide assay including primer-dependant DNA polymerase |
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| US5693517A (en) | 1987-06-17 | 1997-12-02 | Roche Molecular Systems, Inc. | Reagents and methods for coupled high temperature reverse transcription and polymerase chain reactions |
| US5310652A (en) | 1986-08-22 | 1994-05-10 | Hoffman-La Roche Inc. | Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription |
| US5561058A (en) | 1986-08-22 | 1996-10-01 | Hoffmann-La Roche Inc. | Methods for coupled high temperatures reverse transcription and polymerase chain reactions |
| JP2774121B2 (ja) | 1987-07-31 | 1998-07-09 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 標的ポリヌクレオチド配列の選択的増幅 |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| ATE173508T1 (de) | 1988-05-20 | 1998-12-15 | Hoffmann La Roche | Befestigung von sequenzspezifischen proben |
| US5639611A (en) | 1988-12-12 | 1997-06-17 | City Of Hope | Allele specific polymerase chain reaction |
| CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
| US5137806A (en) | 1989-12-11 | 1992-08-11 | Board Of Regents, The University Of Texas System | Methods and compositions for the detection of sequences in selected DNA molecules |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| EP0487218B1 (en) | 1990-10-31 | 1997-12-29 | Tosoh Corporation | Method for detecting or quantifying target nucleic acid |
| IE913930A1 (en) | 1990-11-13 | 1992-06-17 | Siska Diagnostics | Nucleic acid amplification by two-enzyme, self-sustained¹sequence replication |
| US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
| US5994056A (en) | 1991-05-02 | 1999-11-30 | Roche Molecular Systems, Inc. | Homogeneous methods for nucleic acid amplification and detection |
| EP0540997A1 (en) | 1991-11-05 | 1993-05-12 | F. Hoffmann-La Roche Ag | Methods and reagents for HLA class I DNA typing |
| EP0655090B1 (en) | 1992-04-27 | 2000-12-27 | The Trustees Of Dartmouth College | Detection of gene sequences in biological fluids |
| WO1995011995A1 (en) | 1993-10-26 | 1995-05-04 | Affymax Technologies N.V. | Arrays of nucleic acid probes on biological chips |
| US5491063A (en) | 1994-09-01 | 1996-02-13 | Hoffmann-La Roche Inc. | Methods for in-solution quenching of fluorescently labeled oligonucleotide probes |
| US5571673A (en) | 1994-11-23 | 1996-11-05 | Hoffmann-La Roche Inc. | Methods for in-solution quenching of fluorescently labeled oligonucleotide probes |
| EP2474632B1 (en) * | 2002-12-20 | 2015-08-12 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| WO2007103814A2 (en) * | 2006-03-03 | 2007-09-13 | University Of Southern California | Angiogenesis pathway gene polymorphisms for therapy selection |
| EP2126126A2 (en) * | 2007-01-18 | 2009-12-02 | University Of Southern California | Gene polymorphisms in vegf and vegf receptor 2 as markers for cancer therapy |
| WO2008128233A1 (en) * | 2007-04-15 | 2008-10-23 | University Of Chicago | Methods and compositions concerning the vegfr-2 gene (kinase domain receptor, kdr) |
| ES2547568T3 (es) * | 2007-11-30 | 2015-10-07 | Genentech, Inc. | Polimorfismos de VEGF y terapia anti-angiogénesis |
| WO2010124264A2 (en) * | 2009-04-24 | 2010-10-28 | University Of Southern California | Genetic variants in angiogenesis pathway associated with clinical outcome |
| BRPI1015134A2 (pt) * | 2009-08-04 | 2016-04-19 | Hoffmann La Roche | sensibilidade aos inibidores de angiogênese |
-
2012
- 2012-08-28 RU RU2014110271/10A patent/RU2014110271A/ru not_active Application Discontinuation
- 2012-08-28 JP JP2014527619A patent/JP2014526900A/ja active Pending
- 2012-08-28 SG SG10201607224PA patent/SG10201607224PA/en unknown
- 2012-08-28 MX MX2014002311A patent/MX2014002311A/es unknown
- 2012-08-28 WO PCT/EP2012/066630 patent/WO2013030167A1/en not_active Ceased
- 2012-08-28 EP EP12750781.2A patent/EP2751281A1/en not_active Withdrawn
- 2012-08-28 AU AU2012300985A patent/AU2012300985A1/en not_active Abandoned
- 2012-08-28 CN CN201280052573.8A patent/CN104024431A/zh active Pending
- 2012-08-28 KR KR1020147008269A patent/KR20140064923A/ko not_active Withdrawn
- 2012-08-28 CA CA2845381A patent/CA2845381A1/en not_active Abandoned
- 2012-08-29 AR ARP120103188A patent/AR087713A1/es unknown
-
2014
- 2014-02-07 ZA ZA2014/00951A patent/ZA201400951B/en unknown
- 2014-02-26 IL IL231164A patent/IL231164A0/en unknown
- 2014-02-26 US US14/191,040 patent/US20140294768A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013030167A1 (en) | 2013-03-07 |
| SG10201607224PA (en) | 2016-10-28 |
| EP2751281A1 (en) | 2014-07-09 |
| CA2845381A1 (en) | 2013-03-07 |
| IL231164A0 (en) | 2014-04-30 |
| RU2014110271A (ru) | 2015-10-10 |
| CN104024431A (zh) | 2014-09-03 |
| AU2012300985A1 (en) | 2014-02-13 |
| ZA201400951B (en) | 2015-05-27 |
| MX2014002311A (es) | 2014-08-26 |
| NZ620345A (en) | 2016-06-24 |
| KR20140064923A (ko) | 2014-05-28 |
| JP2014526900A (ja) | 2014-10-09 |
| US20140294768A1 (en) | 2014-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| AU2019229353A1 (en) | Mutant calreticulin for the diagnosis of myeloid malignancies | |
| AR106752A1 (es) | Proteínas de unión a pd1 / ctla4 | |
| CY1120246T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
| MX395149B (es) | Terapias de combinación que comprenden un receptor quimérico de antígeno cd19 para el cáncer. | |
| MX392435B (es) | Anticuerpos estables y solubles que inhiben el vegf. | |
| WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
| ES2743232T3 (es) | Métodos para la activación o eliminación controlada de células terapéuticas | |
| PE20170286A1 (es) | Diacuerpos heterodimericos biespecificos y sus usos | |
| AR084831A1 (es) | Terapia anticancer mediante inhibidores de quinasa | |
| MX2012010793A (es) | Composiciones y metodos para la eliminacion de biopeliculas. | |
| MX2013014153A (es) | Biomarcadores paa terapia de inhibidor de hedgehog. | |
| MX2013014622A (es) | Enfermedad tromboembolica. | |
| PE20160192A1 (es) | Composiciones y metodo para tratar condiciones asociadas con el complemento | |
| MX2016016139A (es) | Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5. | |
| EA201590650A1 (ru) | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты | |
| EA201790211A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака | |
| UY33919A (es) | Polimorfismos de un solo nucleótido en el promotor del gen VEGFA y su uso como marcadores predictivos para tratamientos anti-VEGF. | |
| MX2016002529A (es) | Marcadores de riesgo para cardiovasculopatias en pacientes con nefropatia cronica. | |
| AR087713A1 (es) | Capacidad de respuesta a inhibidores de angiogenesis | |
| EA201790642A1 (ru) | Аллель-специфическая терапия для гаплотипов болезни хантингтона | |
| NZ735720A (en) | Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy | |
| GB2523211A (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
| MX2014001736A (es) | Inhibicion de angiogenesis en tumores refractarios. | |
| WO2015036643A3 (es) | Marcador para predecir metástasis del cáncer de mama |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |